Posted by Michael Wonder on 14 Feb 2022
Anxiety mounts for Australian patients as supply chain crunch hits another arthritis drug
14 February 2022 - Patients are reckoning with major shortages of a second rheumatoid arthritis drug in Australia, with manufacturing issues at pharma giant Bristol Myers Squibb leading to lower supplies of its medication Orencia.
The Therapeutic Goods Administration issued a notice last week confirming the company had advised it of shortages of the product, which is used to treat rheumatoid arthritis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis.
